CARE: Rivaroxaban for COVID-19 Outpatients Trial Data
A clinical trial dataset from the CARE study, a multicenter, randomized, open-label, controlled trial registered at clinicaltrials.gov (NCT04757857). The study, authored by Gustavo Bernardes de Figueiredo Oliveira, assessed whether 14 days of rivaroxaban prophylaxis reduced thrombotic events, invasive ventilation, or death in adults with mild or moderate COVID-19 symptoms. Outcomes were centrally adjudicated by an independent clinical events committee.